mynth
08/2025Minority

LGT Capital Partners invests in Nemera

FRANCE Life Sciences / Medical Devices / Medical Consumables REV €450–900M

Context

The deal represents a strategic investment by LGT Capital Partners, Montagu, and Astorg in Nemera, a leading global manufacturer of complex drug delivery devices. The transaction is expected to support Nemera's future growth plans, including enhancing its portfolio, expanding manufacturing capacity, and investing in innovation and operational excellence to meet rising global demand. The investment is closely aligned with the firms' focus on being leading global providers of capital solutions for private equity fund managers and their portfolio companies. With the support of its existing shareholders and the addition of LGT Capital Partners, Nemera is well-positioned to accelerate its growth trajectory and continue to scale globally, providing advanced solutions to its partners and patients worldwide. The deal demonstrates the confidence of the investors in Nemera's strategy and management team, and their commitment to supporting the company's next phase of development. The transaction is expected to have a positive impact on the market, as it will enable Nemera to further strengthen its position in the drug delivery devices market and expand its global footprint.

Nemera, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Nemera (ex Rexam Healthcare Devices and Prescription Retail) is a leading provider of healthcare devices and pharmaceutical packaging solutions. The company's healthcare devices division designs and manufactures a range of products, including inhalers for asthma, insulin pens, and nasal pumps. The prescription retail division produces flacons and security caps for medications sold in pharmacies. With a strong presence in Europe and the United States, the company has a diverse portfolio of products that cater to various healthcare markets, including pulmonary, parenteral, ENT, dermal, and ophthalmic. The company's products are designed to improve patient outcomes and enhance the overall quality of healthcare. With a rich history and a strong commitment to innovation, Rexam Healthcare Devices and Prescription Retail has established itself as a trusted partner in the healthcare industry.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2024
€450–900M
[members only]
[members only]
2023
€450–900M
[members only]
[members only]

Other operations with Nemera

Other operations with Nemera
DateAcquirerTargetCountrySector
10/2018ASTORGNEMERAFRANCEMedical Consumables
02/2014MONTAGU PRIVATE EQUITYNEMERAFRANCEMedical Consumables

Other operations with LGT Capital Partners

Other operations with LGT Capital Partners
DateAcquirerTargetCountrySector
10/2026LGT CAPITAL PARTNERS / EMK CAPITAL / EQT PARTNERSVDK GROEPNETHERLANDSMulti-technical Installation
09/2024LGT CAPITAL PARTNERSH&MV ENGINEERINGIRELANDMulti-technical Installation

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
09/2025CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENTPROTEORFRANCEImplants & Prosthetics
09/2025CAPVEST PARTNERSSTADAGERMANYGenerics / Labs
08/2025TERUMOORGANOXUNITED KINGDOMMedical Devices
08/2025WARBURG PINCUSSEBIAFRANCEDiagnostic Equipment
08/2025PAI PARTNERSINNOVAD GROUPBELGIUMAnimal Health
07/2025PATRICIA INDUSTRIESNOVA BIOMEDICALUNITED STATESDiagnostic Equipment
07/2025BC PARTNERSBIOGARANFRANCEPharma & Biotech
05/2025OTTOBOCKMATTON ORTHOMEDIBELGIUMImplants & Prosthetics
05/2025IK PARTNERSBIOBANKFRANCEImplants & Prosthetics
04/2025PATIENT SQUARE CAPITALPATTERSON COMPANIESUNITED STATESMedical Consumables

REFERENCES

Revenue range: REV €450–900M

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Nemera by LGT Capital Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: nemera

FAQ

What transaction does this page cover?

This page covers the acquisition of a minority stake in Nemera, a French company specialised in Medical Devices, by LGT Capital Partners in 2025. This followed an earlier holding cycle initiated in October 2018, when the company was acquired by Astorg.

What was Nemera’s revenue at the time of the deal?

At the time of the transaction, Nemera’s annual revenue was estimated within the €450–900M range (FY 2024). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.